pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
89
stories
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
22d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
22d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
22d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
22d
Sanofi records €1B+ write-off, ends work on two immunology assets
endpoints
22d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
23d
Do you need oncology experience to land an oncology job?
biospace
23d
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
24d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
25d
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
biopharma dive
25d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
25d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
25d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
25d
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
25d
STAT+: Argenx to buy Forte Biosciences for $2.2B
stat
25d
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
28d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
28d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
Jul 22, 26
6 companies hiring in Cambridge now
biospace
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 16, 26
Chutes & Ladders—Cue lines up new CMO and research head
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 16, 26
Opinion: The growing fang-to-pharmacy pipeline
stat
Jul 15, 26
STAT+: Celcuity’s breast cancer drug approved, its first
stat
Jul 15, 26
STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
stat
Jul 14, 26
As cyclospora illnesses surge to a record, Michigan officials eye lettuce as a possible cause
stat
← prev
page 2 of 3
next →
